Test for Fragile X Syndrome Screening, Diagnosis Gets FDA Clearance
A diagnostic test for fragile X syndrome (FXS) has been cleared by the Food and Drug Administration.
Fragile X Syndrome
CBD Gel Gets Fast Tracked for Behavioral Symptoms Associated With Fragile X Syndrome
The FDA has granted Fast Track designation to Zygel (ZYN002; Zynerba), a cannabidiol gel for the treatment of behavioral symptoms associated with Fragile X syndrome (FXS).
Treatment for Fragile X Syndrome Gets Fast Track Status
A Phase 2 trial of OV101 in males with Fragile X syndrome aged 13 to 22 is planned for later in 2018. OV101 has previously been granted Orphan Drug status for Fragile X and Fast Track status for Angelman syndrome.
